bay86-7548
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2017 (NCT03113617)
Timeline
Indications
Mechanism of action
- Gastrin releasing peptide receptorANTAGONIST
GRPR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03831711 | Phase 1/Phase 2 (Phase 2) | Mar 19, 2019 | General Electric, Stanford University |
| NCT03113617 | Phase 2 | May 1, 2017 | Stanford University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| General Electric | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1